We're constantly growing our expertise in Immunology so that we can continue to discover and develop innovative medicines for patients living with debilitating diseases, such as systemic lupus erythematosus, rheumatoid arthritis, asthma, inflammatory bowel disease, and idiopathic pulmonary fibrosis.

At Genentech our research and discovery efforts into aspects of innate and adaptive immunity are applied to the understanding and treatment of autoimmune, inflammatory and fibrotic disorders. Studying how interactions between the immune system, stromal and epithelial cells, and the environment can become dysregulated in specialized tissues underlies our strategy to develop novel therapies for the treatment of autoimmune, inflammatory, and fibrotic diseases. We rely on human patient samples and biomarker data from observational and interventional clinical trials to define the pathogenic mechanisms and mechanistically distinct patient subsets underlying unmet medical needs in complex chronic diseases.

Science Signal, April 2017

The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation

Nature, December 2015

Therapeutic antibodies reveal Notch control of transdifferentation in the adult lung

Nature, October 2015

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

Science Translational Medicine, August 2015

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma

Nature, October 2014

Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes

Nature, February 2014

A Crohns disease variant in Atg16l1 enhances its degradation by caspase 3

Nature, February 2014

Genetics of rheumatoid arthritis contributes to biology and drug discovery

See the original post here:
Genentech: Immunology